Patents by Inventor Jan Pype

Jan Pype has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240343823
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: February 5, 2024
    Publication date: October 17, 2024
    Applicants: Ablynx N.V., Sanofi
    Inventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
  • Patent number: 11932702
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: March 19, 2024
    Assignees: Ablynx N.V., Sanofi
    Inventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
  • Patent number: 11919966
    Abstract: The present invention relates to immunoglobulin single variable domains that bind GITR and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the polypeptides of the present invention enhance the biological activity of GITR.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: March 5, 2024
    Assignee: Ablynx N.V.
    Inventors: Pieter Deschaght, Sandra Li, Veerle Snoeck, Jan Pype
  • Publication number: 20220411521
    Abstract: The present invention relates to immunoglobulin single variable domains that bind GITR and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the polypeptides of the present invention enhance the biological activity of GITR.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 29, 2022
    Applicant: Ablynx N.V.
    Inventors: Pieter Deschaght, Sandra Li, Veerle Snoeck, Jan Pype
  • Publication number: 20220213215
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: July 7, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
  • Patent number: 11059899
    Abstract: The present invention relates to immunoglobulin single variable domains that bind GITR and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the polypeptides of the present invention enhance the biological activity of GITR.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 13, 2021
    Assignee: Ablynx N.V.
    Inventors: Pieter Deschaght, Sandra Li, Veerle Snoeck, Jan Pype
  • Publication number: 20160151412
    Abstract: The invention relates to a gaseous medication containing xenon, preferably in an amount of less than 75% by volume, for use by inhalation, in combination with at least one NMDA receptor antagonist in the form of a liquid or solid, in particular memantine, for treating, slowing or preventing neurological deterioration consequent upon a neurodegenerative disease, in particular Alzheimer's disease, in a human patient.
    Type: Application
    Filed: July 3, 2014
    Publication date: June 2, 2016
    Inventors: Patrick MICHEL, Jérémie LAVAUR, Etienne HIRSCH, Marc LEMAIRE, Jan PYPE
  • Publication number: 20160067277
    Abstract: The invention relates to a gaseous composition containing xenon as active ingredient for use in preventing or limiting tumour cell migration and/or limiting or preventing metastasis formation in an individual suffering from cancer. The prevention or limitation of tumour cell migration is obtained through the action of the xenon on free cancer cells. The xenon acts on the free cancer cells carried by the blood. The effective volume proportion of xenon is between 5% and 79%, it is preferably at least 50%. The gaseous composition also contains a volume proportion of oxygen (O2) of at least 21%. It is administered by inhalation or insufflation.
    Type: Application
    Filed: March 5, 2014
    Publication date: March 10, 2016
    Inventors: Chui Fung CHONG, Jan Pype
  • Publication number: 20160051581
    Abstract: The invention relates to a gaseous composition containing argon as an active gaseous compound for use to prevent or minimize an ischaemia-reperfusion lesion of a biological material in a recipient individual, during and/or subsequent to the transplantation of said biological material in said recipient individual, wherein said gaseous composition is administered to the recipient individual prior to, during and/or subsequent to the surgical operation aimed at grafting the biological material in said recipient individual.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 25, 2016
    Applicant: L'AIR LIQUIDE SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE
    Inventors: Ira KATZ, Marc LEMAIRE, Jan PYPE
  • Publication number: 20160051580
    Abstract: The invention relates to a gaseous composition containing an active gaseous compound selected from the group made up of Xe and Ar to be used for preventing or minimising an ischaemia-reperfusion lesion of a biological material in a donor patient, while and/or immediately after taking a sample of said biological material from said donor patient, said gaseous composition being administered to the donor patient prior to taking the sample of biological material from said donor patient.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 25, 2016
    Applicant: L'AIR LIQUIDE, SOCIETE ANONYME POUR l'ETUDE ET l'EXPLOITATION DES PROCEDES GEORGES CLAUDE
    Inventors: Ira KATZ, Marc LEMAIRE, Jan PYPE
  • Publication number: 20130071487
    Abstract: The invention relates to a gas composition containing xenon gas for use in preventing the relapse of a patient who has been weaned from at least one psychotropic product which resulted in said patient becoming habituated, the xenon being administered to the patient by inhalation. The composition of the invention contains an effective volume proportion of xenon, in particular from 5 to 70% by volume of xenon. DRAWING: FIG.
    Type: Application
    Filed: May 9, 2011
    Publication date: March 21, 2013
    Applicant: L'Air Liquide, Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude
    Inventors: Baptiste Bessiere, Jan Pype
  • Publication number: 20120301866
    Abstract: The invention relates to a liquid formulation including a liquid solution and at least one gas selected from xenon, argon, hydrogen, H2S, helium, krypton, neon, radon or CO, said gas being dissolved in said liquid solution, for the use thereof as a preservative solution for preserving biological material, in particular cells, tissue and biological organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the intestines. The gas is preferably argon.
    Type: Application
    Filed: January 21, 2011
    Publication date: November 29, 2012
    Applicant: L'Air Liquide, Société Anonyme pour I'Etude et I'Exploitation des Procédés Georges Claude
    Inventors: Andrew Martin, Marc Lemaire, Jan Pype, Chui Fung Chong